{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:00Z","timestamp":1786987500526,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["413517907"],"award-info":[{"award-number":["413517907"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["256073931"],"award-info":[{"award-number":["256073931"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TP1"],"award-info":[{"award-number":["TP1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.coviro.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T19:34:42Z","timestamp":1635276882000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Immunotherapy and therapeutic vaccines for chronic HBV infection"],"prefix":"10.1016","volume":"51","author":[{"given":"Julia","family":"Lang-Meli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Neumann-Haefelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thimme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2021.10.002_bib0005","series-title":"WHO Global hepatitis report 2017","year":"2017"},{"key":"10.1016\/j.coviro.2021.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2021.10.002_bib0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0020","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.181.3.1047","article-title":"The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis","volume":"181","author":"Rehermann","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2021.10.002_bib0030","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.4049\/jimmunol.145.10.3442","article-title":"Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection","volume":"145","author":"Ferrari","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0040","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.1128\/JVI.00867-09","article-title":"The size of the viral inoculum contributes to the outcome of hepatitis B virus infection","volume":"83","author":"Asabe","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0045","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0055","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3389\/fimmu.2019.02240","article-title":"Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy","volume":"10","author":"Heim","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0065","article-title":"TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection","author":"Heim","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2021.10.002_bib0070","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0080","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","article-title":"Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load","volume":"68","author":"Schuch","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0085","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gutjnl-2018-316644","article-title":"Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection","volume":"68","author":"Hoogeveen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0090","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0100","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200298","article-title":"Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection","volume":"217","author":"Fumagalli","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2021.10.002_bib0105","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.4049\/jimmunol.1502061","article-title":"Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination","volume":"196","author":"Zhu","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0110","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0115","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Na\u00efve to Nucleos(t)ide Therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0120","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2020.06.097","article-title":"Nucleic Acid Polymer Therapy for Hepatitis B Virus: Strong Hepatitis B Surface Antigen Decline But Many Unanswered Questions","volume":"160","author":"Sonneveld","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0125","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0130","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/hep.23936","article-title":"The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function","volume":"52","author":"Raziorrouh","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0135","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0140","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1073\/pnas.0801497105","article-title":"Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade","volume":"105","author":"Blackburn","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2021.10.002_bib0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2021.10.002_bib0150","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature19317","article-title":"Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection","volume":"537","author":"He","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2021.10.002_bib0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0165","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0170","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0175","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1172\/JCI120228","article-title":"T cell receptor grafting allows virological control of Hepatitis B virus infection","volume":"129","author":"Wisskirchen","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2021.10.002_bib0180","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0185","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/286533a0","article-title":"Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma","volume":"286","author":"Brechot","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2021.10.002_bib0190","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jmv.24091","article-title":"The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection","volume":"87","author":"Lee","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2021.10.002_bib0200","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN","volume":"64","author":"Fontaine","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2021.10.002_bib0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014626","article-title":"Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection","volume":"6","author":"Cavenaugh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2021.10.002_bib0215","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/hep.29239","article-title":"Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice","volume":"66","author":"Bian","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0220","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0225","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201236","article-title":"Treatment of chronic hepatitis B na\u00efve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)","volume":"13","author":"Al Mahtab","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2021.10.002_sbref0235","first-page":"133","article-title":"Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac","volume":"8","author":"Fern\u00e1ndez","year":"2018","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0240","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fimmu.2013.00214","article-title":"Vaccine adjuvants: mode of action","volume":"4","author":"De Gregorio","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0245","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.0818-9641.2004.01278.x","article-title":"Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen","volume":"82","author":"Aguilar","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0255","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B","volume":"73","author":"Daffis","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0260","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2017.12.007","article-title":"Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism","volume":"68","author":"Niu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0265","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0270","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2017.12.008","article-title":"Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells","volume":"68","author":"Li","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0275","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ni.2573","article-title":"Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection","volume":"14","author":"Huang","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2021.10.002_bib0280","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2021.10.002_bib0285","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J Hepatol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625721001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625721001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:03:47Z","timestamp":1778832227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625721001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":57,"alternative-id":["S1879625721001243"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2021.10.002","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy and therapeutic vaccines for chronic HBV infection","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}